Current treatment guidelines highlight the increased cardiovascular risk associated with type 2 diabetes and identify the need for intensive risk factor management. Dyslipidaemia characterised by elevated serum triglycerides, low levels of high-density lipoprotein cholesterol (HDL-C) and an increase in small, dense low-density lipoprotein cholesterol (LDL-C) particles (the lipid triad), is one of the most important modifiable cardiovascular risk factors in patients with type 2 diabetes. Statins, which are effective in reducing LDL-C, are currently considered the foundation of lipid-lowering treatment in type 2 diabetes, in addition to lifestyle modification. Increasingly, guidelines also identify low HDL-C as an important secondary priority for treatment. Of the available treatment options, both fibrates and nicotinic acid are effective in treating dyslipidaemia associated with type 2 diabetes, although the latter has greater potency in raising HDL-C. Based on its profile of activity, addition of nicotinic acid to primary statin therapy would be a logical strategy in the treatment of diabetic dyslipidaemia. Outcome data from large prospective studies are awaited to confirm the potential morbidity and mortality benefits of this approach.
Miettinen H. , Lehto S., Salomaa V. et al. Impact of diabetes on mortality after first myocardial infarction. Diabetes Care1998;21:69-75.
2.
Haffner SM, Lehto S., Ronnemaa T. et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med1998; 339:229-34.
3.
Kannel WG, McGee DLDiabetes and cardiovascular risk factors: the Framingham Study. Circulation1979;59:8-13.
4.
Kannel WBMetabolic risk factors for coronary heart disease in women: perspectives from the Framingham study. Am Heart J1987 ; 114:413-29.
5.
Barrett-Conner E., Cohn BA, Wingard DL, Edelstein SLWhy is diabetes mellitus a stronger risk factor for fatal ischaemic heart disease in women than men?JAMA1991;265:627-31.
6.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) . JAMA2001;285:2486-97.
7.
De Backer G. , Ambrosioni E., Borch-Johnsen K. et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Executive Summary. Eur Heart J2003;24:1601-10.
8.
International Atherosclerosis Society.Harmonized clinical guidelines on prevention of atherosclerotic vascular disease. Available from www.athero.org. [Accessed 10 July 2005].
9.
Lee W., Min W-K., Chun S. et al. Low-density lipoprotein subclass and its correlating factors in diabetics. Clin Biochem2003;36:657-61.
10.
Gardner CD, Fortmann SP, Krauss RMAssociation of small low-density lipoprotein particles with the incidence of coronary artery disease in men and women. JAMA1996;276:875-81.
11.
Williams PT , Superko HR, Haskell WL et al. Smallest LDL particles are most strongly related to coronary disease progression in men . Arterioscler Thromb Vasc Biol2003;23:314-21.
12.
American Diabetes Association.Dyslipidaemia management in adults with diabetes. Diabetes Care2004;27(suppl 1):S68-S71.
13.
Diabetes Atorvastatin Lipid Intervention (DALI) Study Group.The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidaemia: the DALI study: a double-blind, randomised, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidaemia. Diabetes Care2001;24:1335-41.
14.
Pontrelli L. , Parris W., Adeli K., Cheung RCAtorvastatin treatment beneficially alters the lipoprotein profile and increases low-density lipoprotein particle diameter in patients with combined dyslipidemia and impaired fasting glucose/type 2 diabetes. Metabolism2002;51:33442.
15.
Soedamah-MuthuSS,Colhoun HM, Thomason MJ et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischaemic heart disease. Atherosclerosis2003;167:243-55.
16.
Pyorala K., Pedersen TR, Kjekshus J., Faedeman O., Olsson A., Thorgeirsson G.Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care1997;20:614-20.
17.
Goldberg RB , Mellies MJ, Sacks FM et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the Cholesterol and Recurrent Events (CARE) Trial: the CARE investigators . Circulation1998;98:2513-19.
18.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals. A randomised placebo-controlled trial. Lancet2002;360: 7-22.
19.
Heart Protection StudyCollaborative Group.MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet2003;361:2005-16.
20.
Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet2004;364:685-96.
21.
American Diabetes Association annual meeting 2005 [abstract].
22.
Gordon DJ, Probstfield JL, Garrison RJ et al. High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation1989;79:8-15.
23.
Turner RC, Millns H., Neil HA et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus (UKPDS 23). BMJ1998;316:823-8.
24.
Drexel H., Aczel S., Marte T. et al. Is atherosclerosis in diabetes and impaired fasting glucose driven by elevated LDL cholesterol or by decreased HDL cholesterol?Diabetes Care2005;28:101-07.
25.
Rubins HB, Robins SJ, Collins D. et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med1999;34:410-18.
26.
Rubins HB, Robins SJ, Collins D. et al. Diabetes, plasma insulin and cardiovascular disease. Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch Intern Med2002;162:2597-604.
27.
Diabetes Atherosclerosis InterventionStudy Investigators.Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet2001;357:905-10.
28.
Elkeles RS, Diamond JR, Poulter C. et al. A double-blind placebo-controlled study of bezafibrate: the St. Mary's, Ealing, Northwick Park Diabetes Cardiovascular Disease Prevention (SENDCAP) study. Diabetes Care1998;21:641-8.
29.
Van Gaal LF, Wauters MA, De Leeuw IHThe beneficial effects of modest weight loss on cardiovascular risk factors . Int J Obes Relat Metab Disord1997 ;21(suppl 1):S5-S9.
30.
Nissen SE, Tuzcu EM, Schoenhagen P. et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis. JAMA2004;291:1071-80.
31.
Cannon CP, Braunwald E., McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med2004 ;350:1495-504.
32.
Elisaf M.Effects of fibrates on serum metabolic parameters. Curr Med Res Opin2002;18:269-76.
33.
Shepherd J. , Betteridge J., Van Gaal L. on behalf of a European Consensus Panel.Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome. A position paper developed by a European Consensus Panel. Curr Med Res Opin2005;21:665-82.
34.
Koskinen P. , Manttari M., Manninen V. et al. Coronary heart disease in NIDDM patients in the Helsinki Heart Study. Diabetes Care1992;15:820-5.
35.
Ericsson CG , Hamsten A., Nilsson J., Grip L., de Faire U.Angiographic assessment of bezafibrate on progression of coronary artery disease in young male postinfarction patients . Lancet1996 ;347:849-53.
36.
Frick MH, Syvanne M., Nieminen MS et al. Prevention of angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group. Circulation1997;96:2137-43.
37.
Fruchart JC , Brewer HB, Leitersdorf E.Consensus for the use of fibrates in the treatment of dyslipoproteinemia and CAD. Am J Cardiol1998;81:912-17.
38.
Goldberg A. , Alagona P. Jr, Capuzzi DM et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol2000;85:1100-05.
39.
Guyton JR, Blazing MA, Hagar J. et al. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group. Arch Intern Med2000;160:1177-84.
40.
Canner PL, Furberg CD, Terrin ML, McGovern MEBenefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol2005;95:254-7
41.
Garg A., Grundy SMNicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA1990;264:723-6.
42.
Elam MB, Hunninghake DB, Davis KB et al. Effect of niacin on lipid and lipoprotein levels and glycemia control in patients with diabetes and peripheral arterial disease: the ADMIT study, a randomized trial. JAMA2000;284:1263-70.
43.
Grundy SM, Vega GL, McGovern ME et al. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes. Results of the Assessment of Diabetes control and Evaluation of the Efficacy of Niaspan Trial. Arch Intern Med2002;162:1568-76.
44.
Knopp RH, Alagona P., Davidson M. et al. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia . Metabolism1998;47:1097-104.
45.
McGovern MEUse of nicotinic acid in patients with elevated fasting glucose, diabetes, or metabolic syndrome. Br J Diabetes Vasc Dis2004;4:78-85.
46.
Haffner SM, Alexander CM, Cook TJ et al. Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels. Subgroup analyses in the Scandinavian Simvastatin Survival Study. Arch Intern Med1999;159:2661-7.
47.
Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KAArterial Biology for the Investigation of the Treatment Effects of Reducing cholesterol (ARBITER) 2. A double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation2004;110:3512-17.
